Dee and Jimmy Haslam Contribute $12.5 Million to Combat Blood Cancer at University Hospitals

Dee and Jimmy Haslam Contribute $12.5 Million to Fight Blood Cancer

Dee and Jimmy Haslam, prominent owners of the Cleveland Browns and managing partners of Haslam Sports Group, recently announced a remarkable $12.5 million investment aimed at advancing research and drug development for chronic lymphocytic leukemia (CLL) and other rare blood cancers. This transformational gift will support initiatives at the University Hospitals (UH) Seidman Cancer Center and the Oxford-Harrington Rare Disease Centre in Ohio and England, respectively.

The Haslams' substantial contribution includes $10 million dedicated to accelerating research and drug development through the Oxford-Harrington Rare Disease Centre. This center is well-known for creating groundbreaking treatments for rare conditions, many of which currently have limited or no therapies available. An additional $2.5 million will be allocated to establish an endowed chair in CLL research at the UH Seidman Cancer Center, along with funding for an innovation fund designed to drive advancements in patient care and treatment.

In an inspiring statement, Dee Haslam expressed her gratitude for the opportunity to live a healthy life post-diagnosis of CLL in 2021. She emphasized that this investment is about expanding knowledge and generating new therapies that can empower patients stricken with this disease. “We hope to not only enhance CLL understanding but also uncover cures for other blood disorders,” she remarked, illuminating the hope this initiative brings to many.

Chronic lymphocytic leukemia is noted as the most prevalent form of leukemia among adults. The evolution of targeted therapies over the years has led to its management as a chronic condition. However, the search for a definitive cure continues, and researchers affiliated with the Oxford-Harrington Centre and UH Seidman Cancer Center are dedicated to discovering innovative therapeutics that could one day eradicate the disease.

The partnership established between the Haslams and these medical institutions underscores a shared commitment toward health innovation and patient care. Jonathan Stamler, MD, co-founder of the Harrington Discovery Institute and a professor at Case Western Reserve University, praised the Haslams for their generous investment and the confidence it places in their mission, highlighting that this contribution opens doors for new medicinal advancements in treating blood cancers.

Harrington Discovery Institute has been a pivotal player in medical research since its inception in 2012, with over 227 medicines in development and a commitment to uncovering cures worldwide. David Cameron, former Prime Minister of the U.K. and a member of the Oxford-Harrington Centre Advisory Council, echoed the urgency of addressing the needs for rare diseases and expressed his enthusiasm for the potential breakthroughs this funding could catalyze.

The Haslams’ philanthropic history reflects their long-standing support for initiatives that promote health and innovation. The opening of the UH Haslam Sports Innovation Center in 2023 is a testament to their vision of improving athlete performance and well-being through sports medicine innovation, further showcasing their dedication to health advancements.

Dee Haslam serves on the UH Board of Directors and actively participates in the organization's fundraising campaigns, demonstrating her commitment to improving healthcare access and enhancing treatment options for patients.

In summary, the Haslams' investment not only promises to advance significant research in blood cancers but also hopes to serve as a beacon of hope for patients and communities affected by these devastating diseases. Their collaboration with University Hospitals aims to propel scientific research, foster international partnerships, and ultimately bring new treatments to those in dire need of innovative and effective therapies for rare blood conditions.